|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C20H28N6O3 |
|||
| Molecular Weight | 400.47 | CAS No. | 199986-75-9 | |
| Solubility (25°C)* | In vitro | DMSO | 80 mg/mL (199.76 mM) | |
| Ethanol | 80 mg/mL (199.76 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | CVT-313 is a potent CDK2 inhibitor with an IC50 of 0.5 microM in vitro. It has no effect on other, nonrelated ATP-dependent serine/threonine kinases. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | In cells exposed to CVT-313, hyperphosphorylation of the retinoblastoma gene product is inhibited, and progression through the cell cycle is arrested at the G1/S boundary. The growth of mouse, rat, and human cells in culture is also inhibited by CVT-313 with the IC50 for growth arrest ranging from 1.25 to 20 μM. CVT-313 inhibits Rb hyperphosphorylation[1]. |
Protocol (from reference)
| Cell Assay: |
|
|---|---|
| Animal Study: |
|
Selleck's CVT-313 has been cited by 7 publications
| The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages [ Cancer Cell Int, 2023, 10.1186/s12935-023-03079-2] | PubMed: 37865750 |
| The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages [ Cancer Cell Int, 2023, 23(1):248] | PubMed: 37865750 |
| Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer [ Cell Rep, 2022, 40(7):111218] | PubMed: 35977518 |
| Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway [ Biomedicines, 2022, 10(8)2012] | PubMed: 36009559 |
| Dbf4-Cdc7 (DDK) InhibitorPHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway [ Biomedicines, 2022, 10(8)2012] | PubMed: 36009559 |
| Genetic vulnerabilities upon inhibition of DNA damage response [ Nucleic Acids Res, 2021, gkab643] | PubMed: 34320214 |
| Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer [ Cancer Sci, 2021, 112(12):4909-4919] | PubMed: 34632667 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.